Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
56.44
+0.44 (0.79%)
May 8, 2026, 4:00 PM EDT - Market closed

Xenon Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
-7.5--9.4318.44
Revenue Growth (YoY)
-----48.83%-42.68%
Gross Profit
-7.5--9.4318.44
Selling, General & Admin
84.4179.6368.946.5432.8121.97
Research & Development
328.25300.94210.39167.51105.7775.46
Total Operating Expenses
412.66380.57279.3214.05138.5897.43
Operating Income
-412.66-373.07-279.3-214.05-129.14-78.99
Interest Income
25.6526.8341.9427.628.710.47
Other Non-Operating Income (Expense)
1.861.35-1.063.75-4.83-0.36
Total Non-Operating Income (Expense)
27.5128.1840.8831.373.890.11
Pretax Income
-385.15-344.89-238.42-182.69-125.26-78.89
Provision for Income Taxes
-1.981.02-4.09-0.290.12-0.01
Net Income
-383.17-345.91-234.33-182.39-124.94-77.09
Net Income Attributable to Preferred Dividends
----0.441.8
Net Income to Common
-383.17-345.91-234.33-182.39-124.94-77.09
Shares Outstanding (Basic)
817978676144
Shares Outstanding (Diluted)
817978676144
Shares Change (YoY)
4.16%1.75%16.45%10.48%38.77%26.30%
EPS (Basic)
-4.70-4.36-3.01-2.73-2.06-1.77
EPS (Diluted)
-4.70-4.36-3.01-2.73-2.06-1.77
Shares Outstanding
96.6280.0176.4275.3762.5952.65
Free Cash Flow
-307.25-279.92-184.46-156.73-103.92-71.55
Free Cash Flow Per Share
-3.77-3.53-2.37-2.34-1.72-1.64
Gross Margin
-100.00%--100.00%100.00%
Operating Margin
--4974.27%---1368.91%-428.45%
Profit Margin
--4612.13%---1328.95%-427.85%
FCF Margin
--3732.23%---1101.57%-388.09%
EBITDA
-410.19-370.53-276.74-211.99-127.74-78.09
EBITDA Margin
--4940.36%---1354.02%-423.53%
EBIT
-412.66-373.07-279.3-214.05-129.14-78.99
EBIT Margin
--4974.27%---1368.91%-428.45%
Effective Tax Rate
0.51%-0.29%1.72%0.16%-0.09%0.01%
Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q